Document Detail


Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.
MedLine Citation:
PMID:  23280461     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Prior investigations suggest that olanzapine use declined rapidly after a U.S. Food and Drug Administration (FDA) communication and consensus statement warning of the drug's increased metabolic risks, but whether declines differed by racial-ethnic groups is unknown.
METHODS: Changes in olanzapine use over time by race-ethnicity was assessed among 7,901 Florida Medicaid enrollees with schizophrenia.
RESULTS: Prior to the advisory, 57% of second-generation antipsychotic fills among Hispanics were for olanzapine, compared with 40% for whites or blacks (adjusted risk difference [ARD]=.17, 95% confidence interval [CI]=.13-.20). Olanzapine use declined among all racial-ethnic groups. Although Hispanics had greater olanzapine use than whites in each period, the differences in absolute risk were only 3% by the latest study period (ARD=.03, CI=.01-.04).
CONCLUSIONS: After the FDA communication and consensus statement were issued, differences in olanzapine use between white and Hispanic enrollees narrowed considerably. Identifying high-use subgroups for targeted delivery of drug safety information may help eliminate any existing differences in prescribing.
Authors:
Stacie B Dusetzina; Benjamin L Cook; Alisa B Busch; G Caleb Alexander; Haiden A Huskamp
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Psychiatric services (Washington, D.C.)     Volume:  64     ISSN:  1557-9700     ISO Abbreviation:  Psychiatr Serv     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-02     Completed Date:  2013-06-13     Revised Date:  2014-04-03    
Medline Journal Info:
Nlm Unique ID:  9502838     Medline TA:  Psychiatr Serv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  83-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
African Continental Ancestry Group / statistics & numerical data
Antipsychotic Agents / adverse effects,  metabolism,  therapeutic use*
Benzodiazepines / adverse effects,  metabolism,  therapeutic use*
Confidence Intervals
Continental Population Groups
Diabetes Mellitus / chemically induced
European Continental Ancestry Group / statistics & numerical data
Florida
Hispanic Americans / statistics & numerical data
Humans
Hyperlipidemias / chemically induced
Medicaid
Schizophrenia / drug therapy*,  ethnology*
United States
United States Food and Drug Administration*
Grant Support
ID/Acronym/Agency:
K01MH071714/MH/NIMH NIH HHS; R01 HS0189960/HS/AHRQ HHS; R01 MH091042/MH/NIMH NIH HHS; R01 MH091042/MH/NIMH NIH HHS; T-32MH019733-17/MH/NIMH NIH HHS; T32 MH019733/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Disparities in unmet need for mental health services in the United States, 1997-2010.
Next Document:  Substance screening and referral for substance abuse treatment in an integrated mental health care p...